First Drug Treatment For Myopia Among 14 New EU Filings

 
• By Neena Brizmohun

Vyluma’s eyedrop for treating myopia in children and Vertex’s next-generation triple combination treatment for cystic fibrosis are among the latest drugs that the European Medicines Agency has begun reviewing for potential EU marketing approval.

There are no approved pharmaceutical treatments for myopia available in the EU or the US. • Source: Shutterstock

Vyluma’s NVK002, an atropine-containing eyedrop for treating myopia in children, and sepiapterin, PTC Therapeutics’ drug candidate for phenylketonuria, are among the latest new products that the European Medicines Agency has started reviewing for potential pan-EU marketing approval.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography